News & Updates

Outpatient oritavancin therapy appears to be more effective than inpatient standard-of-care (SoC) in reducing 30-day hospital readmissions or admissions among individuals with acute uncomplicated cellulitis, a recent study has shown.

Treatment with dupilumab helps improve the signs and symptoms of erythrodermic atopic dermatitis, with the improvements occurring as early as the first week and being sustained over time, according to a study. The drug has an acceptable safety profile.

Treatment with oral ritlecitinib improves outcomes in patients with active nonsegmental vitiligo, without any serious adverse events over 48 weeks, results of a study have shown.

An online health model appears to be as effective as in-person care for decreasing functional impairment and depressive symptoms in patients with psoriasis, according to a study.

Individuals with multiple nevi and high genetic predisposition to melanoma appear to have the highest risks of developing second primary melanomas, according to a study.

Treatment with lebrikizumab, when combined with low- to mid-potency topical corticosteroid (TCS), helps reduce disease severity in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD), with a safety profile consistent with that reported in previous AD studies, according to the phase III ADhere trial.

Adalimumab for the treatment of hidradenitis suppurativa appears to be less effective in patients with obesity, a study has found.

In patients with atopic dermatitis (AD), treatment with the IL-13 cytokine-targeting tralokinumab appears to directly or indirectly improves skin microbial dysbiosis, reports a new trial.